Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients

Abstract Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alicja E. Grzegorzewska, Paulina Adamska, Ewa Iwańczyk-Skalska, Kamila Ostromecka, Leszek Niepolski, Wojciech Marcinkowski, Adrianna Mostowska, Wojciech Warchoł, Czesław Żaba, Paweł P. Jagodziński
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9701bf56024d4c1592c2479aeb3ad4fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9701bf56024d4c1592c2479aeb3ad4fa
record_format	dspace
spelling	oai:doaj.org-article:9701bf56024d4c1592c2479aeb3ad4fa2021-12-02T11:45:01ZParaoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients10.1038/s41598-021-86231-02045-2322https://doaj.org/article/9701bf56024d4c1592c2479aeb3ad4fa2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86231-0https://doaj.org/toc/2045-2322Abstract Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its complications. We analysed the PON1 gene (PON1) polymorphisms and serum PON1 (paraoxonase) activity concerning dyslipidaemia and related cardiovascular diseases and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The rs662 AA + AG (OR 1.76, 95%CI 1.10–2.80, P = 0.018), rs854560 TT (OR 1.48, 95%CI 1.04–2.11, P = 0.031), and rs854560 AT + TT (OR 1.28, 95%CI 1.01–1.63, P = 0.040) contributed to the prevalence of atherogenic dyslipidaemia diagnosed by the triglyceride (TG)/HDL-cholesterol ratio ≥ 3.8. The normalized serum PON1 activity positively correlated with atherogenic dyslipidaemia (ẞ 0.67 ± 0.25, P = 0.008). The PON1 rs854560 allele T was involved in the higher prevalence of ischemic cerebral stroke (OR 1.38, 1.02–1.85, P = 0.034). The PON1 rs705379 TT genotype contributed to cardiovascular (HR 1.27, 95% CI 1.03–1.57, P = 0.025) and cardiac (HR 1.34, 95% CI 1.05–1.71, P = 0.018) mortality. All P-values were obtained in multiple regression analyses, including clinical variables. Multifaceted associations of PON1 with dyslipidaemia, ischemic cerebral stroke, and cardiovascular mortality in HD patients provide arguments for the consideration of PON1 and its protein product as therapeutic targets in the prevention of atherosclerosis and its complications in uremic patients.Alicja E. GrzegorzewskaPaulina AdamskaEwa Iwańczyk-SkalskaKamila OstromeckaLeszek NiepolskiWojciech MarcinkowskiAdrianna MostowskaWojciech WarchołCzesław ŻabaPaweł P. JagodzińskiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alicja E. Grzegorzewska Paulina Adamska Ewa Iwańczyk-Skalska Kamila Ostromecka Leszek Niepolski Wojciech Marcinkowski Adrianna Mostowska Wojciech Warchoł Czesław Żaba Paweł P. Jagodziński Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
description	Abstract Paraoxonase 1 (PON1) is known for preventing atherosclerosis through lipid-modifying features, antioxidant activity, anti-inflammatory, anti-apoptosis, anti-thrombosis, and anti-adhesion properties. Uremic patients requiring haemodialysis (HD) are especially prone to atherosclerosis and its complications. We analysed the PON1 gene (PON1) polymorphisms and serum PON1 (paraoxonase) activity concerning dyslipidaemia and related cardiovascular diseases and mortality to show how they associate under uremic conditions modified by maintenance HD treatment. The rs662 AA + AG (OR 1.76, 95%CI 1.10–2.80, P = 0.018), rs854560 TT (OR 1.48, 95%CI 1.04–2.11, P = 0.031), and rs854560 AT + TT (OR 1.28, 95%CI 1.01–1.63, P = 0.040) contributed to the prevalence of atherogenic dyslipidaemia diagnosed by the triglyceride (TG)/HDL-cholesterol ratio ≥ 3.8. The normalized serum PON1 activity positively correlated with atherogenic dyslipidaemia (ẞ 0.67 ± 0.25, P = 0.008). The PON1 rs854560 allele T was involved in the higher prevalence of ischemic cerebral stroke (OR 1.38, 1.02–1.85, P = 0.034). The PON1 rs705379 TT genotype contributed to cardiovascular (HR 1.27, 95% CI 1.03–1.57, P = 0.025) and cardiac (HR 1.34, 95% CI 1.05–1.71, P = 0.018) mortality. All P-values were obtained in multiple regression analyses, including clinical variables. Multifaceted associations of PON1 with dyslipidaemia, ischemic cerebral stroke, and cardiovascular mortality in HD patients provide arguments for the consideration of PON1 and its protein product as therapeutic targets in the prevention of atherosclerosis and its complications in uremic patients.
format	article
author	Alicja E. Grzegorzewska Paulina Adamska Ewa Iwańczyk-Skalska Kamila Ostromecka Leszek Niepolski Wojciech Marcinkowski Adrianna Mostowska Wojciech Warchoł Czesław Żaba Paweł P. Jagodziński
author_facet	Alicja E. Grzegorzewska Paulina Adamska Ewa Iwańczyk-Skalska Kamila Ostromecka Leszek Niepolski Wojciech Marcinkowski Adrianna Mostowska Wojciech Warchoł Czesław Żaba Paweł P. Jagodziński
author_sort	Alicja E. Grzegorzewska
title	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
title_short	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
title_full	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
title_fullStr	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
title_full_unstemmed	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
title_sort	paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9701bf56024d4c1592c2479aeb3ad4fa
work_keys_str_mv	AT alicjaegrzegorzewska paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT paulinaadamska paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT ewaiwanczykskalska paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT kamilaostromecka paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT leszekniepolski paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT wojciechmarcinkowski paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT adriannamostowska paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT wojciechwarchoł paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT czesławzaba paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients AT pawełpjagodzinski paraoxonase1concerningdyslipidaemiacardiovasculardiseasesandmortalityinhaemodialysispatients
_version_	1718395296038256640

Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients

Ejemplares similares